Table 2.
Clinical trials of CAR engineered immune effector cells
| CAR vehicle NCT identifier | Clinical trial phase | Cancer type | Antigen target | Cell source | Construct/Method | Dose | Status | Location |
|---|---|---|---|---|---|---|---|---|
| NK | ||||||||
| NCT03692767 | Early phase 1 | Refractory B-cell lymphoma | CD22 | unknown | unknown | 50–600 × 103/kg | Not yet recruiting | unknown |
| NCT03690310 | Early phase 1 | Refractory B-cell lymphoma | CD19 | unknown | unknown | 50–600 × 103/kg | Not yet recruiting | unknown |
| NCT03824964 | Early phase 1 | Refractory B-cell lymphoma | CD19/CD22 | unknown | unknown | 50–600 ×103/kg | Not yet recruiting | unknown |
| NCT02892695 | Phase 1/2 | ALL, CLL, follicular lymphoma, mantle cell lymphoma, B-PLL, DLBCL | CD19 | NK-92 cell line | CAR.CD19-CD28–41BB- CD3ζ | unknown | Unknown | China |
| NCT03056339 | Phase 1/2 | ALL, CLL, NHL | CD19 | Cord blood | CAR.CD19-CD28- CD3ζ .iCasp9-IL15 | 3 dose levels: 105/kg 106/kg 107/kg |
Phase I portion completed. Phase 2 recruiting | MD Anderson Cancer Center, Houston, TX USA |
| NCT01974479 | Phase 1 | B-ALL | CD19 | Haploidentical donor | CAR.19–41BB-CD3ζ | 0.5 – 5 × 107/kg, and up to 1 × 108/Kg | Suspended for interim review | Singapore |
| NCT00995137 | Phase 1 | B-ALL | CD19 | Haploidentical donor | CAR.19–41BB-CD3ζ | unknown | Completed | St Jude Children’s Research Hospital, Memphis, TN USA |
| NCT04245722 | Phase 1 | B-cell lymphoma, CLL | CD19 +/− CD20 antibody (Rituximab or obinutuzumab) | iPSC derived NK cells | CAR.19-NKG2D-2B4-CD3ζ-IL15RF-hnCD16 | Dose escalation, exact doses unknown | Recruiting | University of Minnesota Masonic Cancer Center, Minnesota USA |
| NCT02742727 | Phase 1/2 | AML, preT-ALL, T-PLL, T-cell LGL, PTCL, angioimmunoblastic T-cell lymphoma, extranodal NK/T-cell lymphoma (nasal type), enteropathy-type intestinal T-cell lymphoma, hepatosplenic T-cell lymphoma | CD7 | NK-92 cell line | CAR.CD7-CD28–41BB-CD3ζ | unknown | Unknown | China |
| NCT03940833 | Phase 1/2 | Multiple myeloma | BCMA | NK-92 cell line | unknown | unknown | Recruiting | China |
| NCT02944162 | Phase 1/2 | AML | CD33 | NK-92 cell line | CAR.CD33-CD28–41BB-CD3ζ | unknown | Unknown | China |
| NCT02839954 | Phase 1/2 | Hepatocellular carcinoma, non-small cell lung cancer, pancreatic carcinoma, triple-negative invasive, breast carcinoma, glioblastoma, colorectal carcinoma, gastric carcinoma | MUC1 | unknown | unknown | unknown | Unknown | China |
| NCT03692663 | Early phase 1 | Castration-resistant prostate cancer | PSMA | unknown | unknown | 0.5–3 × 106/kg | Not yet recruiting | unknown |
| NCT03692637 | Early phase 1 | Epithelial ovarian cancer | Mesothelin | unknown | unknown | 0.5–3 × 106/kg | Not yet recruiting | unknown |
| NCT03415100 | Phase 1 | Solid tumors | NKG2D ligands | Autologous or allogeneic NK | mRNA electroporation | unknown | Recruiting | China |
| NCT03940820 | Phase 1/2 | Solid tumors | ROBO1 | unknown | unknown | Recruiting | China | |
| NCT03941457 | Phase 1/2 | Pancreatic cancer | ROBO1 | unknown | unknown | unknown | Recruiting | China |
| NCT03383978 | Phase 1 | Glioblastoma | HER2 | NK-92 | CAR.HER2. CD28.CD3ζ | 1×107–1×108 intracranial infusion | Recruiting | Germany |
| iNKT cells | ||||||||
| NCT03774654 | Phase 1 | Relapsed/refractory B-cell malignancies | CD19 | Allogeneic NKT cells | CAR.19-CD28-CD3ζ-IL15 | 4 dose levels: 1×107/m2 3×107/m2 1×108/m2 3×108/m2 |
Not yet recruiting | Baylor-Methodist-Texas Children’s, USA |
| NCT03294954 | Phase 1 | Relapsed/refractory neuroblastoma | GD2 | Autologous NKT cells | CAR.GD2-CD28-CD3ζ-IL15 | 4 dose levels: 3×106/m2 1×107/m2 3×107/m2 1×108/m2 |
Recruiting | Baylor-Methodist-Texas Children’s, USA |
| γδ T cells | ||||||||
| NCT02656147 | Phase 1 | B-cell leukemia and lymphoma | CD19 | Allogeneic γδ T cells | unknown | unknown | Not yet recruiting | China |
| NCT04107142 | Phase 1 | Solid tumors | NKG2D ligands | Haploidenticalor allogeneic γδ T cells | unknown | 3 × 108– 3 × 109 cells | Not yet recruiting | Malaysia |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; T-LGL, T-cell large granular leukemia; PLL, prolymphocytic leukemia; PTCL, prolymphocytic T cell leukemia; BCMA, B-cell maturation antigen; DLBCL, diffuse large B cell lymphoma; PSMA, prostate specific membrane antigen; hnCD16, high-affinity, non-cleavable CD16; IL15RF, IL-15 receptor alpha